Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2002, 48, 237-241

https://doi.org/10.14712/fb2002048060237

Rosiglitazone Improves Insulin Resistance, Lipid Profile and Promotes Adiposity in a Genetic Model of Metabolic Syndrome X

O. Šeda1,2, L. Kazdová1, D. Křenová2, Vladimír Křen2,3

1Institute for Clinical and Experimental Medicine, Prague, Czech Republic
2Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic
3Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Received September 2002
Accepted October 2002

References

1. Albrektsen, T., Frederiksen, K. S., Holmes, W. E., Boel, E., Taylor, K., Fleckner, J. (2002) Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes 51, 1042-1051. <https://doi.org/10.2337/diabetes.51.4.1042>
2. Boyle, P. J., King, A. B., Olansky, L., Marchetti, A., Lau, H., Magar, R., Martin, J., (2002) Effects of piogliazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin. Ther. 24, 378-396. <https://doi.org/10.1016/S0149-2918(02)85040-8>
3. Brunmair, B., Gras, F., Neschen, S., Roden, M., Wagner, L., Waldhausl, W., Furnsinn, C. (2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptorgamma-mediated changes in gene expression. Diabetes 50, 2309-2315. <https://doi.org/10.2337/diabetes.50.10.2309>
4. Cullen, P., Lorkowski, S. (2002) Genetics and molecular biology, peroxisome proliferator-activated receptor gamma still full of surprises. Curr. Opin. Lipidol. 13, 335-337. <https://doi.org/10.1097/00041433-200206000-00014>
5. Folch, J., Lees, M., Sloane-Stanley, G. H. (1957) A simple method for isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497-509. <https://doi.org/10.1016/S0021-9258(18)64849-5>
6. Furnsinn, C., Brunmair, B., Meyer, M., Neschen, S., Furtmuller, R., Roden, M., Kuhnle, H. F., Nowotny, P., Schneider, B., Waldhausl, W. (1999) Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br. J. Pharmacol. 128, 1141-1148. <https://doi.org/10.1038/sj.bjp.0702886>
7. Furnsinn, C., Brunmair, B., Neschen, S., Roden, M., Waldhausl, W. (2000) Troglitazone directly inhibits CO2 production from glucose and palmitate in isolated rat skeletal muscle. J. Pharmacol. Exp. Ther. 293, 487-493. <https://doi.org/10.1016/S0022-3565(24)39259-6>
8. Furnsinn, C., Waldhausl, W. (2002) Thiazolidinediones, metabolic actions in vitro. Diabetologia 45, 1211-1223. <https://doi.org/10.1007/s00125-002-0899-1>
9. Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., Freed, M. I. (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106, 679-684. <https://doi.org/10.1161/01.CIR.0000025403.20953.23>
10. Isley, W. L., Oki, J. C. (2001) Hepatotoxicity of thiazolidinediones. Diabetes Obes. Metab. 3, 389-392. <https://doi.org/10.1046/j.1463-1326.2001.00159.x>
11. Jucker, B. M., Schaeffer, T. R., Haimbach, R. E., McIntosh, T. S., Chun, D., Mayer, M., Ohlstein, D. H., Davis, H. M., Smith, S. A., Cobitz, A. R., Sarkar, S. K. (2002) Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats, an in vivo nuclear magnetic resonance study. Diabetes 51, 2066-2073. <https://doi.org/10.2337/diabetes.51.7.2066>
12. Křen, V. (1975) Genetics of the polydactyly-luxate syndrome in the Norway rat, Rattus norvegicus. Acta Univ. Carol. Med. Praha (Monogr.) 68, 1-103.
13. Křen, V., Bílá, V., Kašpárek, R., Křenová, D., Pravenec, M., Rapp, K. (1996) Recombinant inbred and congenic strains of the rat for genetic analysis of limb morphogenesis. Folia Biol. (Praha) 42, 159-166.
14. Lebovitz, H. E. (2002) Differentiating members of the thiazolidinedione class, a focus on safety. Diabetes Metab. Res. Rev. (Suppl.) 2, S23-S29. <https://doi.org/10.1002/dmrr.252>
15. Oakes, N. D., Thalen, P. G., Jacinto, S. M., Ljung, B. (2001) Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50, 1158-1165. <https://doi.org/10.2337/diabetes.50.5.1158>
16. Olefsky, J.M. (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest. 106, 467-472. <https://doi.org/10.1172/JCI10843>
17. Qi, N., Kazdová, L., Zídek, V., Landa, V., Křen, V., Pershadsingh, H. A., St.Lezin, E., Pravenec, M., Kurtz, T. W. (2002) Pharmacogenetic evidence that Cd36 is a key target gene mediating the metabolic effects of pioglitazone. J. Biol. Chem. (in press)
18. Šeda, O., Šedová, L., Kazdová, L., Křenová, D., Křen, V. (2001) Effect of fenofibrate and isotretinoin on metabolic disturbances of PD/Cub rat strain. J. Mol. Med. 79, B27.
19. Šeda, O., Kazdová, L., Křenová, D., Křen, V. (2002) Rosiglitazone fails to improve hypertriglyceridemia and glucose tolerance in CD36-deficient BN.SHR4 congenic rat strain. Physiol. Genomics (in press)
20. Šedová, L., Kazdová, L., Šeda, O., Křenová, D., Křen, V. (2000) Rat inbred PD/Cub strain as a model of dyslipidemia and insulin resistance. Folia Biol. (Praha) 46, 99-106.
21. Sreenan, S., Keck, S., Fuller, T., Cockburn, B., Burant, C. F. (1999) Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am. J. Physiol. 276, E1119-1129.
22. Vestergaard, H., Lund, S., Pedersen, O. (2001) Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. J. Intern. Med. 250, 406-414. <https://doi.org/10.1046/j.1365-2796.2001.00898.x>
23. Vrána, A., Kazdová L. (1970) Insulin sensitivity of rat adipose tissue and of diaphragm in vitro. Effect of the type of dietary carbohydrate. Life Science 9, 257-265. <https://doi.org/10.1016/0024-3205(70)90314-0>
24. Vrána, A., Poledne, R., Fábry, P., Kazdová, L. (1978) Palmitate and glucose oxidation by diaphragm of rats with fructose-induced hypertriglyceridemia. Metabolism 27, 885-888. <https://doi.org/10.1016/0026-0495(78)90131-2>
25. Vrána, A., Kazdová L., Dobešová, Z., Kuneš, J., Křen, V., Bílá, V., Štolba, P., Klimeš, I. (1993) Triglyceridemia, glucoregulation, and blood pressure in various rat strains. Effects of dietary carbohydrates. Ann. N. Y. Acad. Sci. 683, 57-68. <https://doi.org/10.1111/j.1749-6632.1993.tb35692.x>
26. Watkins, S. M., Reifsnyder, P. R., Pan, H., German, J. B., Leiter, E. H. (2002) Lipid metabolome-wide effects of the peroxisome proliferator-activated receptor γ agonist rosiglitazone. J. Lipid Res. 43, 1809-1817. <https://doi.org/10.1194/jlr.M200169-JLR200>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive